US 12,029,708 · Application 17/817,927 · Granted Jul 9, 2024
US 12,029,708
Alkoxy compounds for disease treatment
Estimated expiration
October 3, 2028
2y 26d remaining
Earliest effective filing
Oct 3, 2008
+ 20 years
Oct 3, 2028
PTA +0d
Oct 3, 2028
TD applied
Oct 3, 2028
Final
Oct 3, 2028
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).
Calculation details
Base term
- Filing date
- August 5, 2022
- Earliest effective filing
- October 3, 2008
- Issue date
- July 9, 2024
- PTA
- 0 days
- Base expiry (before PTA)
- October 3, 2028
October 3, 2008 + 20 years = October 3, 2028
- Continuation of application 16/865,195, filed May 1, 2020, issued as US 11,446,261
- Continuation of application 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
- Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
- Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
- Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 14/631,779, filed Feb 25, 2015
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
- Continuation of application 14/631,779, filed Feb 25, 2015
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
- Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
- Continuation of application 14/631,779, filed Feb 25, 2015
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
- Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
- Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
- Continuation of application 14/631,779, filed Feb 25, 2015
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- Continuation of application 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
- Continuation of application 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
- Continuation of application 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
- Continuation of application 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
- Continuation of application 14/631,779, filed Feb 25, 2015
- Continuation of application 13/111,679, filed May 19, 2011, issued as US 8,981,153
- Continuation of application 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
- PRO60/977,957 — Provisional — not used for base term
- PRO61/066,353 — Provisional — not used for base term
- PRO61/051,657 — Provisional — not used for base term
- PRO61/043,127 — Provisional — not used for base term
- PRO61/060,083 — Provisional — not used for base term
Terminal disclaimers
TD caps expiration to October 3, 2028
US 9,957,224· Application 13/887,243Capping patent
Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
- Filing date
- May 3, 2013
- Earliest effective filing
- May 3, 2013
- Issue date
- May 1, 2018
- PTA
- 0 days
- Calculated expiration
- May 3, 2033
May 3, 2013 + 20y = May 3, 2033
US 12,029,708· Application 17/817,927(from application 17/817,927)Capping patent
Alkoxy compounds for disease treatment
- Filing date
- Aug 5, 2022
- Earliest effective filing
- Oct 3, 2008
- Issue date
- Jul 9, 2024
- PTA
- 0 days
- Calculated expiration
- Oct 3, 2028
Continuation of 16/865,195, filed May 1, 2020, issued as US 11,446,261
Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Oct 3, 2008 + 20y = Oct 3, 2028
US 11,446,261· Application 16/865,195
Alkoxy compounds for disease treatment
- Filing date
- May 1, 2020
- Earliest effective filing
- Oct 3, 2008
- Issue date
- Sep 20, 2022
- PTA
- 0 days
- Calculated expiration
- Oct 3, 2028
Continuation of 16/043,019, filed Jul 23, 2018, issued as US 10,639,286
Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Continuation of 15/672,031, filed Aug 8, 2017, issued as US 10,188,615
Continuation of 15/260,127, filed Sep 8, 2016, issued as US 9,737,496
Continuation of 14/631,763, filed Feb 25, 2015, issued as US 9,458,088
Continuation of 14/631,779, filed Feb 25, 2015
Continuation of 13/111,679, filed May 19, 2011, issued as US 8,981,153
Continuation of 12/287,039, filed Oct 3, 2008, issued as US 7,982,071
Oct 3, 2008 + 20y = Oct 3, 2028
US 7,982,071· Application 12/287,039
Alkoxy compounds for disease treatment
- Filing date
- Oct 3, 2008
- Earliest effective filing
- Oct 3, 2008
- Issue date
- Jul 19, 2011
- PTA
- +413 days
- Calculated expiration
- Nov 20, 2029
Oct 3, 2008 + 20y + 413d PTA = Nov 20, 2029
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/817,927 · US 12,029,708
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,029,708: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12029708Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.